 - Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months, symptomatic congestive heart failure, unstable angina pectoris within 3 months prior to entry study, myocardial infarction within 6 months prior to study entry, ongoing cardiac arrhythmia excluding atrial fibrillation, uncontrolled hypertension systolic blood pressure 150 mmHg or diastolic blood pressure 90 mmHg, despite optimal medical management, pulmonary hemorrhagebleeding event CTCAE Grade 2 within 4 weeks of first dose of study drug, or any other hemorrhagebleeding event CTCAE Grade 3 within 4 weeks of first dose of study drug, serious non-healing wound, ulcer, or bone fracture, evidence or history of bleeding diathesis or coagulopathy. 